Rasche Franz Maximilian, Keller Frieder, von Müller Lutz, Czock David, Lepper Philipp M
Division of Nephrology, Department of Internal Medicine I, University Hospital of Ulm, Ulm, Germany.
Contrib Nephrol. 2007;157:109-13. doi: 10.1159/000102313.
Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN.
Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73 m2) and further disease activity (triangle downGFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months.
The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria >1.0 g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03).
A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called 'point of no return' with progressive IgAN.
环磷酰胺和大剂量类固醇已被用作进展性IgA肾病(IgAN)的有限诱导疗法,以减少肾功能丧失和蛋白尿。我们评估了环磷酰胺脉冲疗法(CyP)和霉酚酸(MPA)序贯治疗对进展性IgAN患者肾功能的影响。
20例进展性IgAN且伴有晚期肾衰竭(中位肾小球滤过率[GFR]为每分钟22 ml/1.73 m²),在接受环磷酰胺(CyP;n = 18)或类固醇脉冲治疗(n = 2)后仍有疾病活动(GFR每月下降-0.8 ml/min)的患者,接受霉酚酸酯每日1 g治疗,中位治疗时间为27个月。
线性回归分析显示,肾功能的每月丧失从CyP治疗前的-2.4 ml/min显著降低至CyP/MPA治疗时的-0.12 ml/min(p = 0.0009)。估计肾脏生存时间显著延长,中位延长65个月(p = 0.0014)。在MPA治疗期间,蛋白尿从1.7 g/l显著降至0.4 g/l(p = 0.015)。在Cox回归分析中,仅蛋白尿>1.0 g/l是CyP/MPA治疗期间肌酐翻倍的独立危险因素(p = 0.03)。
即使是对于进展性IgAN已过所谓“不可逆转点”的患者,CyP/MPA序贯治疗也可能阻止或减缓肾功能丧失并减少蛋白尿。